Almirall SA ALM
BME · Spain · Health Technology
€10.20-0.36 (-3.41%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
VIENNA, October 01, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced long-term results from ADlong, a Phase 3b open-label extension study evaluating the efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The late-breaking results of this long-term clinical study are presented at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna, A
VIENNA, September 30, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, today announced its scientific programme at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna from 30 September to 3 October 2026. As Gold Sponsor of this year’s congress, Almirall will present more than 20 abstracts on clinical and real-world evidence spanning atopic dermatitis (AD), psoriasis (PsO) and actinic keratosis (AK), and
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.